Erratum: Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12R? 2 or IL-18Ra (Gene Therapy (2011) 18 898909 DOI:10.1038/gt.2011.37);Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12RΒ2 or IL-18Rα

Gene Therapy

Volumn 18, Issue 9, 2011, Pages 898-909

  Choi, I K ^a   Lee, J S ^b   Zhang, S N ^b   Park, J ^b   Lee, K M ^d   Sonn, C H ^d   Yun, C O ^a,b,c  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Hanyang University   (South Korea)

^d Korea University College of Medicine   (South Korea)

Author keywords

cancer immunogene therapy; IL 12; IL 18; oncolytic adenovirus; T cells expressing IL 12R 2 or IL 18R

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR ALPHA; ONCOLYTIC ADENOVIRUS;

ANIMAL CELL; ANTITUMOR GENE; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL DIFFERENTIATION; CELL INFILTRATION; CELL SURVIVAL; CONTROLLED STUDY; HELPER CELL; IMMUNOGENETICS; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADENOVIRIDAE; MURINAE; MUS;

EID: 80052588142     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.72     Document Type: Erratum

References (42)

1. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-168. (Pubitemid 34229390)
2. Wigginton JM, Wiltrout RH. IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin Biol Ther 2002; 2: 513-524. (Pubitemid 34716734)
3. Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006; 12: 5859-5868. (Pubitemid 44629619)
4. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-gamma- inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 1996; 173: 230-235. (Pubitemid 26381401)
5. Kohno K, Kataoka J, Ohtsuki T, Suemoto Y, Okamoto I, Usui M et al. IFN-gammainducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 1997; 158: 1541-1550. (Pubitemid 127469506)
6. Tomura M, Zhou XY, Maruo S, Ahn HJ, Hamaoka T, Okamura H et al. A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3-cells. J Immunol 1998; 160: 4738-4746. (Pubitemid 28215306)
7. Tsutsui H, Nakanishi K, Matsui K, Higashino K, Okamura H, Miyazawa Y et al. IFNgamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996; 157: 3967-3973. (Pubitemid 126449306)
8. Okamura H, Nagata K, Komatsu T, Tanimoto T, Nukata Y, Tanabe F et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 1995; 63: 3966-3972.
9. Micallef MJ, Yoshida K, Kawai S, Hanaya T, Kohno K, Arai S et al. In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 1997; 43: 361-367. (Pubitemid 27102222)
10. Marshall DJ, Rudnick KA, McCarthy SG, Mateo LR, Harris MC, McCauley C et al. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Vaccine 2006; 24: 244-253. (Pubitemid 41790427)
11. Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T et al. IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. Int Immunol 2000; 12: 151-160. (Pubitemid 30088307)
12. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001; 12: 53-72. (Pubitemid 32294587)
13. Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM et al. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. Cancer Res 2005; 65: 1063-1070. (Pubitemid 40216469)
14. Ahn HJ, Maruo S, Tomura M, Mu J, Hamaoka T, Nakanishi K et al. A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. J Immunol 1997; 159: 2125-2131. (Pubitemid 127681000)
15. Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998; 101: 1441-1452. (Pubitemid 28145262)
16. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004; 58: 24-38. (Pubitemid 38117046)
17. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202: 275-293. (Pubitemid 39576919)
18. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003; 21: 713-758. (Pubitemid 37174546)
19. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11-22. (Pubitemid 38111131)
20. Osaki T, Peron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M et al. IFN-gammainducing factor/IL-18 administration mediates IFN-gamma-and IL-12-independent antitumor effects. J Immunol 1998; 160: 1742-1749. (Pubitemid 28106460)
21. Marshall E. Sciencescope. Science 1995; 268: 1555.
22. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90: 2541-2548. (Pubitemid 27413462)
23. Kim J, Kim JH, Choi KJ, Kim PH, Yun CO. E1A-and E1B-double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther 2007; 18: 773-786. (Pubitemid 47502844)
24. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806. (Pubitemid 30159332)
25. Yamanaka K, Hara I, Nagai H, Miyake H, Gohji K, Micallef MJ et al. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol Immunother 1999; 48: 297-302. (Pubitemid 29434189)
26. Hara I, Nagai H, Miyake H, Yamanaka K, Hara S, Micallef MJ et al. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 2000; 7: 83-90. (Pubitemid 30080991)
27. Oshikawa K, Shi F, Rakhmilevich AL, Sondel PM, Mahvi DM, Yang NS. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA. Proc Natl Acad Sci USA 1999; 96: 13351-13356.
28. Shiratori I, Suzuki Y, Oshiumi H, Begum NA, Ebihara T, Matsumoto M et al. Recombinant interleukin-12 and interleukin-18 antitumor therapy in a guinea-pig hepatoma cell implant model. Cancer Sci 2007; 98: 1936-1942. (Pubitemid 350002200)
29. Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003; 63: 6378-6386. (Pubitemid 37255187)
30. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15: 749-795.
31. Darwich L, Coma G, Pena R, Bellido R, Blanco EJ, Este JA et al. Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology 2009; 126: 386-393.
32. Fricke I, Mitchell D, Mittelstadt J, Lehan N, Heine H, Goldmann T et al. Mycobacteria induce IFN-gamma production in human dendritic cells via triggering of TLR2. J Immunol 2006; 176: 5173-5182.
33. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1995; 1: 890-893.
34. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368. (Pubitemid 29028508)
35. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000; 60: 3239-3246. (Pubitemid 30407923)
36. Jinushi M, Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci 2009; 100: 1389-1396.
37. Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH, Lee M et al. Therapeutic and tumorspecific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther 2010; 18: 264-274.
38. Scharton TM, Scott P. Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993; 178: 567-577. (Pubitemid 23218205)
39. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002; 2: 957-964. (Pubitemid 37323216)
40. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998; 161: 3400-3407.
41. Chang JT, Segal BM, Nakanishi K, Okamura H, Shevach EM. The costimulatory effect of IL-18 on the induction of antigen-specific IFN-gamma production by resting T cells is IL-12 dependent and is mediated by up-regulation of the IL-12 receptor beta2 subunit. Eur J Immunol 2000; 30: 1113-1119. (Pubitemid 30216228)
42. Yun CO, Kim E, Koo T, Kim H, Lee YS, Kim JH. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 2005; 12: 61-71. (Pubitemid 39665244)